Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invent Medic Sweden ABXSAT:IMS -4.72%26 3-Year EBITDA Growth Rate is 52.80% as of Jun. 2026, which is 106% above its 10-year median of 25.60. GuruFocus rates XSAT:IMS with a GF Score™ of 26/100 and a GF Value™ of kr0.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Invent Medic Sweden AB ranks better than 89.24% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 52.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 47.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Invent Medic Sweden AB was 52.80% per year. The lowest was -32.60% per year. And the median was 25.60% per year.
Invent Medic Sweden AB (XSAT:IMS) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Invent Medic Sweden AB 3-Year EBITDA Growth Rate Related Terms
XSAT:IMS vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Invent Medic Sweden AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invent Medic Sweden AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Invent Medic Sweden AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Invent Medic Sweden AB's 3-Year EBITDA Growth Rate falls into.
Invent Medic Sweden AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 52.80% mean?
Invent Medic Sweden AB (XSAT:IMS) has a 3-Year EBITDA Growth Rate of 52.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Invent Medic Sweden AB and its competitors. This is 106% above median its historical median of 25.60. According to the industry distribution chart, Invent Medic Sweden AB ranks #74 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 10.8%.
Is Invent Medic Sweden AB's 3-Year EBITDA Growth Rate too high?
Invent Medic Sweden AB's current 3-Year EBITDA Growth Rate of 52.80% is 106% above median its 10-year median of 25.60. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Invent Medic Sweden AB's value of 52.80% is 568.4% above this industry median. Based on the distribution chart, Invent Medic Sweden AB ranks #74 out of 688 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Invent Medic Sweden AB has a GF Score™ of 26/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Invent Medic Sweden AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Invent Medic Sweden AB ranks #74 out of 688 companies for 3-Year EBITDA Growth Rate. This places Invent Medic Sweden AB in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.90. Invent Medic Sweden AB's value of 52.80% is 568.4% above this benchmark. While the company's 10-year median is 25.60 vs. the industry median of 7.90, Invent Medic Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invent Medic Sweden AB's current 3-Year EBITDA Growth Rate of 52.80% is 568.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Invent Medic Sweden AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invent Medic Sweden AB's current 3-Year EBITDA Growth Rate is 52.80%, which is 106% above median its own 10-year median of 25.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invent Medic Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Invent Medic Sweden AB (XSAT:IMS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.13, compared to a current price of kr0.10 — trading 22.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 52.80%, which is 106% above median its 10-year median of 25.60 and 568.4% above the Medical Devices & Instruments industry median of 7.90. Invent Medic Sweden AB's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Invent Medic Sweden AB (XSAT:IMS), the current 3-Year EBITDA Growth Rate is 52.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Invent Medic Sweden AB (XSAT:IMS) Overvalued in 2026?
Based on GuruFocus' analysis, Invent Medic Sweden AB stock appears to be undervalued.
The current stock price of kr0.10 is trading 22.3% below its estimated GF Value™ of kr0.13.
GuruFocus considers Invent Medic Sweden AB to be Modestly Undervalued.
Key valuation signals for XSAT:IMS:
3-Year EBITDA Growth Rate: 52.80% (106% above median its 10-year median of 25.60)
GF Value™: kr0.13 vs. price of kr0.10 (22.3% below fair value)
Industry Position: 568.4% above the Medical Devices & Instruments median (#74 of 688)
No single metric tells the full story. See the XSAT:IMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Invent Medic Sweden AB develops and markets its product - Efemia bladder support, a vaginal medical device for the treatment of female urinary incontinence.
26GF Score
Get the complete analysis for XSAT:IMS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:IMS has been successfully added to your 
